Patients that received aromatase inhibitor treatment in addition to tamoxifen therapy did not have a significantly decreased risk of meningioma compared with patients without either treatment (aHR = 0.59, 95% CI = 0.31–1.15). The gene discussed is CYP19A1; the disease is meningioma.